Shares in Alector (NASDAQ:ALEC) are tumbling 28.7% at 12:30 p.m. EDT on Wednesday over concerns COVID-19 could negatively impact patient enrollment and monitoring in clinical-stage trials of AL001.
Full Answer
How much is a share of Alector stock worth?
One share of ALEC stock can currently be purchased for approximately $17.51. How much money does Alector make? Alector has a market capitalization of $1.42 billion and generates $21.10 million in revenue each year. The company earns $-190.23 million in net income (profit) each year or ($0.52) on an earnings per share basis.
Is Alector a buy or sell on the New York Times?
- The New York Times Alector has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings. According to analysts' consensus price target of $40.33, Alector has a forecasted upside of 130.3% from its current price of $17.51.
When is Alector's next quarterly earnings release?
Alector is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022. View our earnings forecast for Alector. How were Alector's earnings last quarter?
How did Alector (Alec) perform in the Q4 earnings?
Alector, Inc. (NASDAQ:ALEC) posted its quarterly earnings data on Thursday, November, 4th. The company reported $1.49 EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.46) by $1.95. The company had revenue of $182.41 million for the quarter, compared to analyst estimates of $407.41 million.
Is Alector a buy right now?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alector in the last year. There are currently 1 sell rating, 1 hold rating...
When is Alector's next earnings date?
Alector is scheduled to release its next quarterly earnings announcement on Tuesday, August 2nd 2022. View our earnings forecast for Alector .
How were Alector's earnings last quarter?
Alector, Inc. (NASDAQ:ALEC) released its quarterly earnings results on Thursday, November, 4th. The company reported $1.49 earnings per share for t...
What price target have analysts set for ALEC?
6 brokerages have issued 12-month target prices for Alector's shares. Their forecasts range from $6.00 to $57.00. On average, they expect Alector's...
Who are Alector's key executives?
Alector's management team includes the following people: Dr. Tillman Ulf Gerngross Ph.D. , Co-Founder & Chairman (Age 58, Pay $60k) Dr. Arnon Ro...
What is Arnon Rosenthal's approval rating as Alector's CEO?
4 employees have rated Alector CEO Arnon Rosenthal on Glassdoor.com . Arnon Rosenthal has an approval rating of 100% among Alector's employees. Th...
Who are some of Alector's key competitors?
Some companies that are related to Alector include Beam Therapeutics (BEAM) , Fate Therapeutics (FATE) , Bavarian Nordic A/S (BVNRY) , Twist Bi...
What other stocks do shareholders of Alector own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Alector investors own include Editas Medicine (EDIT) , NV...
When did Alector IPO?
(ALEC) raised $177 million in an initial public offering (IPO) on Thursday, February 7th 2019. The company issued 9,300,000 shares at $18.00-$20.00...
What does it mean when an insider sells a stock?
When insiders sell shares, it indicates their concern in the company’s prospects or that they view the stock as being overpriced. Either way, this signals an opportunity to go short on the stock. Insider sales should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a selling decision. Below is a look at a few recent notable insider sales. For more, check out Benzinga's insider transactions platform. Tesla The Trade: Tesla, Inc. (
What is the Vickers top buyer and seller report?
Daily – Vickers Top Buyers & Sellers for 11/08/2021 The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
What does it mean when an insider sells a stock?
When insiders sell shares, it indicates their concern in the company’s prospects or that they view the stock as being overpriced. Either way, this signals an opportunity to go short on the stock. Insider sales should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a selling decision. Below is a look at a few recent notable insider sales. For more, check out Benzinga's insider transactions platform. Tesla The Trade: Tesla, Inc. (
What is the Vickers top buyer and seller report?
Daily – Vickers Top Buyers & Sellers for 11/08/2021 The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Does AL001 increase progranulin levels?
Progranulin Levels Increase to Normal Ranges Multiple Biomark ers of Disease Showed Improvement from Baseline with AL001 Treatment, Including GFAP, a Prognostic Marker for FTD Associated with Brain Atrophy FTD-GRN Patients Showed a Slowing of Clinical Progression with AL001 Treatment Relative to GENFI2 Matched Control Cohort Data from Phase 2 Study Presented at Clinical Trials of Alzheimer Disease Conference; Management to Host Webcast to Review Results Today at 4:00 p.m. ET BOSTON, Nov. 12, 2021
What is the Alector focus?
Alector's focus is on immunoneurology and most specifically on microglia. Microglia are a type of immune cells found in the CNS tissue. Microglia are involved in all sorts of functions in the brain, ranging from synaptic organization to debris removal. In recent years, scientists have increasingly found evidence to support that microglial dysfunction is at least partially responsible for neurodegenerative disorders rather than merely a symptom of them. Alector intends to use antibodies to target microglia with the hope that properly regulated microglial function will address some of the root causes of neurodegenerative disorders and provide meaningful relief for patients.
What is an ALEC?
Alector (ALEC) is a clinical-stage biotech company looking to treat neurological disorders like frontotemporal dementia and Alzheimer's disease and also potentially cancer as well. Alector's lead program is AL001 for treatment of frontotemporal dementia patients with a single GRN mutation, and it has been given an orphan drug designation from ...
What happened
Shares in Alector ( ALEC -0.93% ) are tumbling 28.7% at 12:30 p.m. EDT on Wednesday over concerns COVID-19 could negatively impact patient enrollment and monitoring in clinical-stage trials of AL001.
So what
The biotech company 's AL001 is being evaluated for use in frontotemporal dementia patients with a progranulin gene (PGRN) mutation.
NASDAQ: ALEC
Worry that enrollment in AL001's trials could be slower than expected and missed doses and follow-up visits could create obstacles to analyzing trial results appear to be outweighing otherwise encouraging data.
Now what
Frontotemporal dementia is a devastating disease without any treatments approved by the Food and Drug Administration. Of the 170,000 people in the U.S. and European Union with this disease, roughly 15,000 have a mutation that could conceivably be addressed by AL001.
Premium Investing Services
Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.